New app aims to ease chemo side effects for cancer patients
NCT ID NCT07218874
First seen Jun 24, 2026 · Last updated Jul 08, 2026 · Updated 3 times
Summary
This study is testing whether a mobile app that combines daily symptom reports with Fitbit data can help cancer patients better manage side effects during chemotherapy. Fifty adults with solid tumors will use the app for 90 days, receiving tips for mild symptoms and alerts to contact their doctor for more serious ones. The goal is to see if the app is easy to use and improves quality of life and communication with the care team.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Mobile Symptom Monitoring and Alert App
- What this could lead to
- If successful, this app could help cancer patients better manage chemotherapy side effects and improve communication with their care team.
- What could go wrong
- This is a small, early feasibility study with only 50 participants, so results may not apply to all patients. The app is a monitoring tool, not a treatment, so it won't directly affect the cancer itself.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
39 people
The number who actually took part.
- Started
-
Feb 2026
- Finished
-
Jun 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Receiving chemotherapy at the UPMC Hillman Cancer Center for any solid tumor cancer at any stage with at least two cycles remaining; * age 18 years or older; * ability to read and write in English; * sufficient performance status to participate in research (e.g., Karnofsky performance status of 60-100%); and * owns and uses an Android smartphone or an iPhone capable of running the study apps. Exclusion Criteria: * under 18 years old; and * unable to read and write in English
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to dozens of diseases
- Can a gentler blood thinner shield cancer patients from new clots?
- Can more phone calls after cancer surgery keep patients out of the hospital?
- Live music meets virtual reality: can a Three-Session program reach advanced cancer patients in palliative care?
- Matching cancer survivors to the right level of support
- Can colorectal surgery patients go home in two days?